Feedback

Brazil starts production of Russian Sputnik V vaccine

Source : 112 Ukraine

This week the Russian Direct Investment Fund and Uniao Quimica will file the application for urgent use of Sputnik V in Brazil
14:55, 14 January 2021

Sputnik V coronavirus vaccine
AFP

One of the leading Brazilian pharmaceutical companies - Uniao Quimica – has started the production of the Russian Sputnik V vaccine against coronavirus as RIA News reported.

“The Russian Direct Investment Fund has provided all necessary documentation and materials,” the message said.

This week the Russian Direct Investment Fund and Uniao Quimica will file the application for urgent use of Sputnik V in Brazil. The vaccination of the population by Russian medicine has already started. At the end of October, the Russian Fund, Uniao Quimica Farmaceutica Nacional and the government of the Brazilian Paraná state filed to the Health Regulatory Agency of Brazil the set of documents for registration of Sputnik V.

Related: Israel plans to provide free Covid-19 vaccines to Holocaust survivors worldwide

According to the developers, in the first quarter of 2021, the Russian Direct Investment Fund will supply to Brazil 10 million dozes of the vaccine; the first batches expected in January. According to Head of the Fund Kirill Dmitriev, totally, 150 million doses of vaccine should be provided to Brazil this year.

Besides, the Fund and Uniao Quimica will offer all BRICS countries to create an operative group on fighting against Covid-19 and cooperate on vaccines.

On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.

Related: Ukraine holds talks with companies that registered Covid-19 vaccines, - Healthcare Minister

The vaccine is produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and the Russian Binnopharm Company.

Earlier, the Health Ministry of Russia released to the civil circulation the first batch of Sputnik V vaccine against the coronavirus.

In summer, the medicine has successfully passed two stages of trials on volunteers at the age of 18 up to 60 who formed the immune response and antibodies against SARS-CoV-2. The post-registration trial, including participation old people and people from other groups of risk started in September. After the third interim analysis, Sputnik V showed over 91% of efficacy; this rate reached 100% for severe cases of Covid-19.

Watch review of Year 2020 here:

 

 

 

 

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more